Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation

Qing Zhang, Phd, Christoph Heuck, MD, Pingping Qu, PhD, Saad Z Usmani, MD, FACP, Ryan Williams, Yiming Zhou, PhD, Clyde Bailey, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1865.

https://doi.org/10.1182/blood.V122.21.1865.1865

Published: 2013

Journal Articles

Prediction of cytogenetic abnormalities with gene expression profiles

Yiming Zhou, Qing Zhang, Owen Stephens, Christoph J. Heuck, Erming Tian, Jeffrey R. Sawyer, Marie-Astrid Cartron-Mizeracki, Pingping Qu, Jason Keller, Joshua Epstein, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2012) 119 (21): e148–e150.

https://doi.org/10.1182/blood-2011-10-388702

Published: 2012

Includes: Supplemental data

Journal Articles

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification

Owen W. Stephens, Qing Zhang, Pingping Qu, Yiming Zhou, Shweta Chavan, Erming Tian, David R. Williams, Joshua Epstein, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2012) 119 (2): 503–512.

https://doi.org/10.1182/blood-2011-07-367052

Published: 2012

Includes: Supplemental data

Journal Articles

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Yiming Zhou, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Owen Stephens, Erming Tian, PhD, Jeffrey Sawyer, PhD, Marie-Astrid Cartron-Mizeracki, MS, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 629.

https://doi.org/10.1182/blood.V118.21.629.629

Published: 2011

Journal Articles

Molecularly Classified High Risk Myeloma Cells with Low ROS Levels and High Nestin Expression Have High Proliferation Index and GEP80 Score,

Sarah K. Johnson, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 3953.

https://doi.org/10.1182/blood.V118.21.3953.3953

Published: 2011

Journal Articles

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Erming Tian, PhD, Saad Usmani, MD, FACP, Yiming Zhou, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 3932.

https://doi.org/10.1182/blood.V118.21.3932.3932

Published: 2011

Journal Articles

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

John D. Shaughnessy, Jr, Pingping Qu, Saad Usmani, Christoph J. Heuck, Qing Zhang, Yiming Zhou, Erming Tian, Ichiro Hanamura, Frits van Rhee, Elias Anaissie, Joshua Epstein, Bijay Nair, Owen Stephens, Ryan Williams, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie

Blood (2011) 118 (13): 3512–3524.

https://doi.org/10.1182/blood-2010-12-328252

Published: 2011

Includes: Supplemental data

Journal Articles

Identification of early growth response protein 1 ( EGR-1 ) as a novel target for JUN -induced apoptosis in multiple myeloma

Lijuan Chen, Siqing Wang, Yiming Zhou, Xiaosong Wu, Igor Entin, Joshua Epstein, Shmuel Yaccoby, Wei Xiong, Bart Barlogie, John D. Shaughnessy, Jr, Fenghuang Zhan

Blood (2010) 115 (1): 61–70.

https://doi.org/10.1182/blood-2009-03-210526

Published: 2010

Journal Articles

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Yiming Zhou, Lijuan Chen, Bart Barlogie, MD, PhD, Owen Stephens, PhD, Xiaosong Wu, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Sarah Waheed, MD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, John D Shaughnessy, Jr.

Blood (2009) 114 (22): 1804.

https://doi.org/10.1182/blood.V114.22.1804.1804

Published: 2009

Journal Articles

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Bijay Nair, John D. Shaughnessy, Jr, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, Bart Barlogie

Blood (2009) 113 (26): 6572–6575.

https://doi.org/10.1182/blood-2009-02-207803

Published: 2009

Journal Articles

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Bijay Nair, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Jackie Szymonifka, John Crowley, PhD, John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 1691.

https://doi.org/10.1182/blood.V112.11.1691.1691

Published: 2008

Journal Articles

C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications

Klaus Podar, MD, MSc, PhD, Jing Zhang, MS, Giovanni Tonon, MD, PHD, Clemens Grabher, MSc, PHD, Samir Lababidi, PHD, Marc S Raab, MD, Sonia Vallet, MD, Yiming Zhou, PHD, Marie-Astrid Cartron, MS, Martin Sattler, PhD, Dharminder Chauhan, JD, PHD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2750.

https://doi.org/10.1182/blood.V112.11.2750.2750

Published: 2008

Journal Articles

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Damir Herman, PhD, Owen Stephens, PhD, Erming Tian, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, Jeffrey Sawyer, Ph.D., John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 250.

https://doi.org/10.1182/blood.V112.11.250.250

Published: 2008

Journal Articles

The BCL9 Oncogene Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic and Angiogenic Properties to Myeloma Cells

Mala Mani, Ph.D., Jui Dutta, Yunyu Zhang, Daniel E Carrasco, Yiming Zhou, Moshe Gatt, Bart Barlogie, John D. Shaughnessy, Jr., PhD, Kenneth C Anderson, MD, Daniel Ruben Carrasco, M.D., Ph.D.

Blood (2008) 112 (11): 648.

https://doi.org/10.1182/blood.V112.11.648.648

Published: 2008

Journal Articles

Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy

John D. Shaughnessy, Jr., PhD, Pingping Qu, MD, Ricky Edmondson, PhD, Damir Herman, PhD, Yiming Zhou, PhD, Erming Tian, Frits van Rhee, MD, PhD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, Elias Anaissie, Ya-wei Qiang, Joshua Epstein, PhD, Shmuel Yaccoby, PhD, David Williams, Fenghuang Zhan, PhD, Owen Stephens, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2008) 112 (11): 733.

https://doi.org/10.1182/blood.V112.11.733.733

Published: 2008

NARROW

Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation

Prediction of cytogenetic abnormalities with gene expression profiles

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Molecularly Classified High Risk Myeloma Cells with Low ROS Levels and High Nestin Expression Have High Proliferation Index and GEP80 Score,

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

Identification of early growth response protein 1 ( EGR-1 ) as a novel target for JUN -induced apoptosis in multiple myeloma

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications

Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma

The BCL9 Oncogene Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic and Angiogenic Properties to Myeloma Cells

Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only